Business Context and Reporting Period
This Form 8-K was filed by TherapeuticsMD, Inc. on September 7, 2021, reporting events as of September 2, 2021. The filing addresses ongoing patent litigation concerning the Company's product IMVEXXY (estradiol vaginal inserts), used to treat moderate-to-severe dyspareunia associated with menopause.
Key Financial Metrics
This filing is a Current Report regarding legal proceedings and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Legal Developments
- Litigation Status: The Company is engaged in patent infringement litigation against Teva Pharmaceuticals USA, Inc. regarding Teva's Abbreviated New Drug Application (ANDA) for a generic version of IMVEXXY.
- Statutory Stay Extension: On September 2, 2021, the U.S. District Court for the District of New Jersey made public an order extending the statutory 30-month stay that prevents the FDA from granting final approval of Teva's ANDA.
- Extension Mechanism: The stay will be extended by the number of days the litigation proceedings remain stayed. The duration of this litigation stay depends on further actions by Teva.
- Patent Expiration: The IMVEXXY patents identified in the dispute expire in 2032 or 2033.
Guidance, Outlook, and Risks
The filing includes standard forward-looking statements regarding the Company's objectives and strategies. Management notes that actual results may differ due to risks and uncertainties, specifically highlighting the effects of the IMVEXXY Paragraph IV litigation. The Company undertakes no duty to update these statements.
Key Facts for Investor Verification
- Verify the current status of the litigation stay and any subsequent filings by Teva that could alter the duration of the FDA approval block.
- Confirm the specific expiration dates (2032 or 2033) of the patents in question to assess the remaining exclusivity period.
- Review the Company's most recent Form 10-K and 10-Q for detailed financial health metrics, as this 8-K contains no financial data.
- Monitor for any updates on the "Risk Factors" section in future filings regarding the potential impact of generic competition on IMVEXXY sales.